A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Sponsor: Takeda
Listed as NCT04206605, this PHASE3 trial focuses on Angioedema and remains completed. Sponsored by Takeda, it has been updated 14 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Nov 2022 — Jan 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 9 earlier versions
-
Jul 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Jul 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Jun 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
Status: Not Yet Recruiting → Active Not Recruiting
-
May 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE3
Status: Recruiting → Not Yet Recruiting
-
Mar 2020 — May 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2020 — Mar 2020 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
- Takeda Development Center Americas, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .